Array
(
[Ovarian Cancer] => Array
(
[Austin] => https://www.survivornet.com/austin/
[Baltimore] => https://www.survivornet.com/baltimore/
[Charlotte] => https://www.survivornet.com/charlotte/
[Cleveland] => https://www.survivornet.com/cleveland/
[Columbus] => https://www.survivornet.com/columbus/
[Dallas / Ft. Worth] => https://www.survivornet.com/dallas-ftworth/
[Denver] => https://www.survivornet.com/denver/
[Detroit] => https://www.survivornet.com/detroit/
[Indianapolis] => https://www.survivornet.com/indianapolis-ovarian-cancer/
[Louisville] => https://www.survivornet.com/louisville/
[Memphis] => https://www.survivornet.com/memphis/
[Minneapolis] => https://www.survivornet.com/minneapolis/
[Nashville] => https://www.survivornet.com/nashville/
[Phoenix] => https://www.survivornet.com/phoenix/
[Portland] => https://www.survivornet.com/portland/
[Salt Lake City] => https://www.survivornet.com/salt-lake-city/
[San Antonio] => https://www.survivornet.com/san-antonio/
[San Diego] => https://www.survivornet.com/san-diego/
[San Francisco] => https://www.survivornet.com/san-francisco/
[San Jose] => https://www.survivornet.com/san-jose/
[Seattle] => https://www.survivornet.com/seattle/
) [Multiple Myeloma] => Array
(
[Ann Arbor] => https://www.survivornet.com/ann-arbor-michigan-multiple-myeloma-treatment/
[Miami] => https://www.survivornet.com/miami-florida-multiple-myeloma-treatment/
[Phoenix] => https://www.survivornet.com/phoenix-arizona-multiple-myeloma-treatment/
) [Glioma] => Array
(
[Midwest] => https://www.survivornet.com/midwest/
[Mountain States] => https://www.survivornet.com/glioma-mountain-states/
[Southeast] => https://www.survivornet.com/southeast/
) [Prostate Cancer] => Array
(
[Houston] => https://www.survivornet.com/houston-advanced-prostate-cancer/
[Miami] => https://www.survivornet.com/miami-advanced-prostate-cancer/
[Philadelphia] => https://www.survivornet.com/philadelphia/
) [Non-Hodgkin Lymphoma] => Array
(
[Atlanta ] => https://www.survivornet.com/atlanta-advanced-large-b-cell/
[Houston] => https://www.survivornet.com/houston-advanced-large-b-cell/
[Orange County] => https://www.survivornet.com/orange-county-advanced-large-b-cell/
) )
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Summary The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the affected eye.
View Eligibility Criteria Eligibility Criteria Inclusion Criteria: Males or females of any race at least 18 years of age Clinical diagnosis of primary uveal melanoma involving the posterior uveal tract in the study eye Planned enucleation or brachytherapy of the study eye due to uveal melanoma Exclusion Criteria: Uveal melanoma in the study eye originating in the anterior uveal tract (iris) Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia) Woman who is pregnant or lactating
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
San Francisco California, 94109, United States
Denver Colorado, 80401, United States
Leawood Kansas, 66211, United States
Boston Massachusetts, 02114, United States
Grand Rapids Michigan, 49546, United States
Royal Oak Michigan, 48073, United States
Portland Oregon, 97239, United States
Philadelphia Pennsylvania, 19107, United States
How clear is this clinincal trial information?
Sign Up Sign up now for access to powerful tools, top experts, and customized information to help you fight cancer.
Personalized content tailored to your profile and disease type Access exclusive patient guides Breaking treatment information and expert perspectives and more... Sign Up Now Already have an account? Sign In
Sign Up Already have an account? Sign In
Sign In Don't have an account? Sign Up
Password reset is unavailable because your account was created using 'Sign Up with Google. To continue, please use the Google sign-in button below. Don't have an account? Sign Up